Harmony Biosciences Holdings, Inc.(HRMY)Earnings, Financials & Key Ratios

HRMY•NASDAQ

$32.78

$1.89B mkt cap·12.1× P/E·Price updated May 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryCommercial Rare Disease Biopharma

AboutHarmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.Show more

Revenue$868M+21.5%
EBITDA$232M+8.1%
Net Income$159M+9.1%
EPS (Diluted)2.71+8.0%
Gross Margin77.16%-1.2%
EBITDA Margin26.75%-11.0%
Operating Margin24%-10.1%
Net Margin18.27%-10.2%
ROE20.75%-19.7%
ROIC59.53%+53.2%
Debt/Equity0.02-91.6%
Interest Coverage14.23+30.5%

Technical→

HRMY Key Insights

Harmony Biosciences Holdings, Inc. (HRMY) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Company is almost debt free
✓Excellent 3Y average ROE of 25.4%
✓FCF machine: 40.1% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 40.3%
✓Healthy 5Y average net margin of 22.7%

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

HRMY Price & Volume

Harmony Biosciences Holdings, Inc. (HRMY) stock price & volume — 10-year historical chart

Loading chart...

HRMY Growth Metrics

Harmony Biosciences Holdings, Inc. (HRMY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years40.3%

3 Years25.64%

TTM21.51%

Profit CAGR

10 Years-

5 Years-

3 Years-4.37%

TTM9.07%

EPS CAGR

10 Years-

5 Years-

3 Years-3.01%

TTM7.97%

Return on Capital

10 Years-10.52%

5 Years26.03%

3 Years26.48%

Last Year22.62%

HRMY Recent Earnings

Harmony Biosciences Holdings, Inc. (HRMY) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 7/12 qtrs (58%)●Beat Revenue 4/12 qtrs (33%)

Q1 2026Latest

Feb 24, 2026

EPS

$0.38

Est $0.84

-54.8%

Revenue

$244M

Est $240M

+1.4%

Q4 2025

Nov 4, 2025

EPS

$0.87

Est $0.92

-5.4%

Revenue

$239M

Est $240M

-0.2%

Q3 2025

Aug 5, 2025

EPS

$0.68

Est $0.78

-12.8%

Revenue

$200M

Est $220M

-8.9%

Q2 2025

May 6, 2025

EPS

$0.78

Est $0.59

+32.2%

Revenue

$185M

Est $206M

-10.3%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 24, 2026	$0.38vs $0.84-54.8%	$244Mvs $240M+1.4%
Q4 2025	Nov 4, 2025	$0.87vs $0.92-5.4%	$239Mvs $240M-0.2%
Q3 2025	Aug 5, 2025	$0.68vs $0.78-12.8%	$200Mvs $220M-8.9%
Q2 2025	May 6, 2025	$0.78vs $0.59+32.2%	$185Mvs $206M-10.3%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
JAZZJazz Pharmaceuticals plcDirect Competitor	14.34B	228.57	-39.14	4.88%	0.66%	0.71%	1.26
AVPTAvePoint, Inc.Direct Competitor	2.22B	10.27	68.47	26.93%	8.3%	7.95%	0.02
AXSMAxsome Therapeutics, Inc.Direct Competitor	11.46B	222.63	-60.50	65.55%	-26.59%	-260.01%	2.73
INVAInnoviva, Inc.Direct Competitor	1.91B	22.52	6.82	18.52%	118.91%	46.47%	0.23
SUPNSupernus Pharmaceuticals, Inc.Direct Competitor	2.96B	51.45	-75.66	8.63%	-3.74%	-2.73%	0.04
NKTRNektar TherapeuticsProduct Competitor	1.67B	85.09	-8.75	-43.89%	-192.87%	-356.81%	0.95
PTCTPTC Therapeutics, Inc.Product Competitor	5.52B	66.61	8.56	114.51%	39.44%
RAREUltragenyx Pharmaceutical Inc.Product Competitor	2.55B	25.93	-4.45	20.13%	-91.03%	-6.08%

Compare HRMY vs Peers

Harmony Biosciences Holdings, Inc. (HRMY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs JAZZ

Most directly comparable listed peer for HRMY.

Scale Benchmark

vs MCK

Larger-name benchmark to compare HRMY against a more recognizable public peer.

Peer Set

Compare Top 5

vs JAZZ, AVPT, AXSM, INVA

HRMY Income Statement

Harmony Biosciences Holdings, Inc. (HRMY) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Sales/Revenue	0	6M	159.74M	305.44M	437.86M	582.02M	714.73M	868.45M
Revenue Growth %	-	-	2564.59%	91.21%	43.35%	32.93%	22.8%	21.51%
Cost of Goods Sold	184K	1.58M	27.74M	55.52M	83.48M	121.24M	156.81M	198.34M
COGS % of Revenue	-	26.31%	17.36%	18.18%	19.07%	20.83%	21.94%	22.84%
Gross Profit	-184K▲ 0%	4.42M▲ 2501.1%	132M▲ 2887.9%	249.92M▲ 89.3%	354.37M▲ 41.8%	460.79M▲ 30.0%	557.92M▲ 21.1%	670.11M▲ 20.1%
Gross Margin %	-	73.69%	82.64%	81.82%	80.93%	79.17%	78.06%	77.16%
Gross Profit Growth %	-	2501.09%	2887.87%	89.33%	41.79%	30.03%	21.08%	20.11%
Operating Expenses	41.44M	150.32M	115.02M	162.39M	234.19M	268.76M	367.09M	461.64M
OpEx % of Revenue	-	2507.46%	72%	53.17%	53.49%	46.18%	51.36%	53.16%
Selling, General & Admin	29.07M	80.73M	95.57M	132.03M	163.3M	192.69M	221.27M	272.05M
SG&A % of Revenue	-	1346.57%	59.83%	43.23%	37.3%	33.11%	30.96%	31.33%
Research & Development	12.37M	69.59M	19.45M	30.37M	70.89M	76.06M	145.82M	189.59M
R&D % of Revenue	-	1160.88%	12.17%	9.94%	16.19%	13.07%	20.4%	21.83%
Other Operating Expenses	0	0	0	0	0	0	0	0
Operating Income	-41.44M▲ 0%	-145.9M▼ 252.1%	16.99M▲ 111.6%	87.53M▲ 415.3%	120.19M▲ 37.3%	192.03M▲ 59.8%	190.83M▼ 0.6%	208.47M▲ 9.2%
Operating Margin %	-	-2433.76%	10.63%	28.66%	27.45%	32.99%	26.7%	24%
Operating Income Growth %	-	-252.09%	111.64%	415.29%	37.31%	59.78%	-0.63%	9.25%
EBITDA	-41.26M	-142.69M	27.22M	106.37M	143.57M	216.39M	214.94M	232.32M
EBITDA Margin %	-	-2380.22%	17.04%	34.82%	32.79%	37.18%	30.07%	26.75%
EBITDA Growth %	-	-245.88%	119.08%	290.73%	34.98%	50.72%	-0.67%	8.08%
D&A (Non-Cash Add-back)	184K	3.21M	10.24M	18.84M	23.39M	24.36M	24.11M	23.85M
EBIT	-41.44M	-145.9M	-8.72M	61.62M	123.48M	197.15M	209.3M	229.71M
Net Interest Income	0	-6.07M	-28.22M	-23.97M	-15.67M	-9.03M	1.05M	7.28M
Interest Income	0	0	0	224K	3.13M	14.73M	18.54M	21.92M
Interest Expense	0	6.07M	28.22M	24.19M	18.8M	23.76M	17.5M	14.65M
Other Income/Expense	1.54M	-6.07M	-53.93M	-50.1M	-15.5M	-18.63M	978K	6.59M
Pretax Income	-39.9M▲ 0%	-151.98M▼ 280.9%	-36.94M▲ 75.7%	37.43M▲ 201.3%	104.69M▲ 179.7%	173.4M▲ 65.6%	191.8M▲ 10.6%	215.06M▲ 12.1%
Pretax Margin %	-	-2535.06%	-23.13%	12.25%	23.91%	29.79%	26.84%	24.76%
Income Tax	0	0	0	2.83M	-76.78M	44.54M	46.31M	56.38M
Effective Tax Rate %	0%	0%	0%	7.56%	-73.35%	25.69%	24.14%	26.21%
Net Income	-39.9M▲ 0%	-151.98M▼ 280.9%	-36.94M▲ 75.7%	34.6M▲ 193.6%	181.47M▲ 424.5%	128.85M▼ 29.0%	145.49M▲ 12.9%	158.69M▲ 9.1%
Net Margin %	-	-2535.06%	-23.13%	11.33%	41.44%	22.14%	20.36%	18.27%
Net Income Growth %	-	-280.91%	75.69%	193.65%	424.52%	-28.99%	12.91%	9.07%
Net Income (Continuing)	-39.9M	-151.98M	-36.94M	34.6M	181.47M	128.85M	145.49M	158.69M
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0
EPS (Diluted)	-1.42▲ 0%	-2.94▼ 107.0%	-1.10▲ 62.6%	0.58▲ 152.7%	2.97▲ 412.1%	2.13▼ 28.3%	2.51▲ 17.8%	2.71▲ 8.0%
EPS Growth %	-	-107.04%	62.59%	152.73%	412.07%	-28.28%	17.84%	7.97%
EPS (Basic)	-1.42	-2.94	-1.12	0.60	3.07	2.17	2.56	2.76
Diluted Shares Outstanding	49.24M	63.68M	57.85M	59.21M	61.1M	60.37M	57.87M	58.54M
Basic Shares Outstanding	49.24M	63.68M	56.89M	57.53M	59.17M	59.47M	56.88M	57.49M
Dividend Payout Ratio	-	-	-	-	-	-	-	-

HRMY Balance Sheet

Harmony Biosciences Holdings, Inc. (HRMY) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Total Current Assets	86.68M	31.5M	262.89M	284.44M	400.29M	451.07M	579.25M	907.01M
Cash & Short-Term Investments	83.52M	24.46M	228.63M	234.31M	323.12M	353.46M	467.19M	752.5M
Cash Only	83.52M	24.46M	228.63M	234.31M	243.78M	311.66M	453M	752.5M
Short-Term Investments	0	0	0	0	79.33M	41.8M	14.19M	0
Accounts Receivable	0	4.25M	22.18M	34.84M	54.74M	74.14M	83.03M	96.79M
Days Sales Outstanding	-	259.06	50.67	41.64	45.63	46.49	42.4	40.68
Inventory	0	1.09M	3.82M	4.43M	4.3M	5.36M	7.2M	5.36M
Days Inventory Outstanding	-	251.82	50.31	29.14	18.79	16.15	16.75	9.86
Other Current Assets	2.46M	261K	1.3M	3.22M	8.79M	5.54M	8.12M	52.37M
Total Non-Current Assets	2.6M	75.21M	164.18M	149M	273.58M	360.38M	419.95M	364.62M
Property, Plant & Equipment	1.58M	1.33M	938K	4.12M	573K	371K	3.38M	0
Fixed Asset Turnover	-	4.51x	170.30x	74.17x	764.14x	1568.79x	211.52x	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	72.19M	162.34M	143.92M	160.95M	137.11M	113.26M	89.42M
Long-Term Investments	500K	0	0	0	22.57M	72.17M	108.87M	107.13M
Other Non-Current Assets	522K	1.69M	902K	967K	3.55M	6.57M	194.43M	18.37M
Total Assets	89.28M▲ 0%	106.7M▲ 19.5%	427.07M▲ 300.2%	433.44M▲ 1.5%	673.87M▲ 55.5%	811.45M▲ 20.4%	999.2M▲ 23.1%	1.27B▲ 27.3%
Asset Turnover	-	0.06x	0.37x	0.70x	0.65x	0.72x	0.72x	0.68x
Asset Growth %	-	19.51%	300.25%	1.49%	55.47%	20.42%	23.14%	27.26%
Total Current Liabilities	7.23M	19.89M	134.54M	53.77M	78.88M	163.78M	175.08M	252.13M
Accounts Payable	1.46M	6.36M	2.56M	1M	3.79M	17.73M	13.74M	0
Days Payables Outstanding	2.9K	1.47K	33.63	6.58	16.55	53.38	31.99	-
Short-Term Debt	0	0	0	2M	2M	15M	16.25M	20M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	313K	753K	100.31M	1	1.62M	107.3M	4.35M	232.13M
Current Ratio	11.99x	1.58x	1.95x	5.29x	5.07x	2.75x	3.31x	3.60x
Quick Ratio	11.99x	1.53x	1.93x	5.21x	5.02x	2.72x	3.27x	3.58x
Cash Conversion Cycle	-	-961.15	67.34	64.19	47.87	9.26	27.17	-
Total Non-Current Liabilities	523K	98.4M	195.35M	193.16M	192.15M	180.68M	164.96M	149.28M
Long-Term Debt	324.2M	97.95M	194.25M	189.98M	189.65M	178.57M	163.02M	0
Capital Lease Obligations	0	0	0	2.4M	0	0	822K	0
Deferred Tax Liabilities	-324.46M	0	0	0	0	0	0	0
Other Non-Current Liabilities	-323.68M	450K	1.1M	777K	2.5M	2.11M	1.13M	149.28M
Total Liabilities	7.75M	118.29M	329.89M	246.94M	271.03M	344.46M	340.05M	401.41M
Total Debt	324.2M	97.95M	194.25M	195.74M	191.65M	193.57M	181.41M	20M
Net Debt	240.68M	73.49M	-34.38M	-38.56M	-52.14M	-118.09M	-271.6M	-732.5M
Debt / Equity	3.98x	-	2.00x	1.05x	0.48x	0.41x	0.28x	0.02x
Debt / EBITDA	-	-	7.14x	1.84x	1.33x	0.89x	0.84x	0.09x
Net Debt / EBITDA	-	-	-1.26x	-0.36x	-0.36x	-0.55x	-1.26x	-3.15x
Interest Coverage	-	-24.03x	0.60x	3.62x	6.39x	8.08x	10.91x	14.23x
Total Equity	81.53M▲ 0%	-11.59M▼ 114.2%	97.18M▲ 938.8%	186.51M▲ 91.9%	402.84M▲ 116.0%	466.99M▲ 15.9%	659.15M▲ 41.1%	870.22M▲ 32.0%
Equity Growth %	-	-114.21%	938.84%	91.92%	115.99%	15.93%	41.15%	32.02%
Book Value per Share	1.66	-0.18	1.68	3.15	6.59	7.74	11.39	14.86
Total Shareholders' Equity	81.53M	-11.59M	97.18M	186.51M	402.84M	466.99M	659.15M	870.22M
Common Stock	1K	0	1K	1K	1K	1K	1K	1K
Retained Earnings	-242.67M	-422.86M	-488.19M	-453.6M	-272.13M	-143.28M	2.22M	160.9M
Treasury Stock	0	0	0	0	0	0	0	0
Accumulated OCI	-2K	0	0	0	-151K	2K	66K	346K
Minority Interest	0	0	0	0	0	0	0	0

HRMY Cash Flow Statement

Harmony Biosciences Holdings, Inc. (HRMY) cash flow — operating, investing & free cash flow history

Line item	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Cash from Operations	-38.8M	-75.44M	-2.98M	98.56M	144.47M	219.39M	219.82M	348.2M
Operating CF Margin %	-	-1258.32%	-1.87%	32.27%	32.99%	37.69%	30.76%	40.09%
Operating CF Growth %	-	-94.43%	96.04%	3401.74%	46.58%	51.86%	0.2%	58.4%
Net Income	-39.9M	-151.98M	-36.94M	34.6M	181.47M	128.85M	145.49M	0
Depreciation & Amortization	184K	3.8M	10.24M	21.08M	25.05M	24.36M	24.11M	0
Stock-Based Compensation	1.08M	9.91M	4.69M	16.11M	26.91M	31.7M	42.6M	0
Deferred Taxes	0	0	25.75M	0	0	-13.42M	-29.3M	0
Other Non-Cash Items	2.06M	59.44M	4.91M	24.59M	-82.06M	12.85M	44.23M	256.38M
Working Capital Changes	-164K	3.39M	-11.63M	2.19M	-6.89M	35.03M	-7.32M	91.82M
Change in Receivables	0	-4.25M	-17.92M	-12.67M	-19.9M	-19.4M	-8.89M	-13.75M
Change in Inventory	0	-1.09M	-2.73M	-609K	135K	-1.07M	-1.83M	1.84M
Change in Payables	-610K	0	-3.8M	0	0	8.95M	-5.38M	3.95M
Cash from Investing	-1.34M	-127.15M	-2M	-100.3M	-141.83M	-46.44M	-67.48M	-39.65M
Capital Expenditures	-1.34M	-149K	-2M	-298K	-172K	-312K	-1.15M	0
CapEx % of Revenue	-	2.49%	1.25%	0.1%	0.04%	0.05%	0.16%	0.04%
Acquisitions	0	0	-2M	0	0	-36.97M	-33.07M	0
Investments	-	-	-	-	-	-	-	-
Other Investing	0	-127M	2M	-100M	-141.66M	0	-26.5M	-39.65M
Cash from Financing	21.61M	143.77M	209.16M	7.42M	6.84M	-105.55M	-11M	-9.05M
Debt Issued (Net)	0	100M	79.42M	-500K	-2M	-1.25M	-15M	-16.25M
Equity Issued (Net)	1000K	0	-184K	0	0	-1000K	1000K	1000K
Dividends Paid	0	0	0	0	0	0	0	0
Share Repurchases	-3.2M	0	-167K	0	0	-100M	0	0
Other Financing	-185K	43.77M	129.93M	7.92M	8.84M	-3.79M	-2.5M	-3M
Net Change in Cash	-18.53M▲ 0%	-58.82M▼ 217.5%	204.17M▲ 447.1%	5.68M▼ 97.2%	9.47M▲ 66.9%	67.4M▲ 611.3%	141.34M▲ 109.7%	299.5M▲ 111.9%
Free Cash Flow	-40.14M▲ 0%	-75.58M▼ 88.3%	-4.99M▲ 93.4%	98.26M▲ 2070.3%	144.29M▲ 46.9%	219.07M▲ 51.8%	218.67M▼ 0.2%	347.89M▲ 59.1%
FCF Margin %	-	-1260.8%	-3.12%	32.17%	32.95%	37.64%	30.59%	40.06%
FCF Growth %	-	-88.3%	93.4%	2070.3%	46.85%	51.83%	-0.19%	59.09%
FCF per Share	-0.82	-1.19	-0.09	1.66	2.36	3.63	3.78	5.94
FCF Conversion (FCF/Net Income)	0.97x	0.50x	0.08x	2.85x	0.80x	1.70x	1.51x	2.19x
Interest Paid	0	4.23M	0	19.83M	16.36M	20.05M	17.32M	0
Taxes Paid	0	0	0	0	0	48.23M	79.64M	0

HRMY Key Ratios

Harmony Biosciences Holdings, Inc. (HRMY) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-48.94%	-434.57%	-86.32%	24.39%	61.58%	29.63%	25.84%	20.75%
Return on Invested Capital (ROIC)	-	-56.98%	20.43%	62.3%	36.15%	41.17%	38.87%	59.53%
Gross Margin	-	73.69%	82.64%	81.82%	80.93%	79.17%	78.06%	77.16%
Net Margin	-	-2535.06%	-23.13%	11.33%	41.44%	22.14%	20.36%	18.27%
Debt / Equity	3.98x	-	2.00x	1.05x	0.48x	0.41x	0.28x	0.02x
Interest Coverage	-	-24.03x	0.60x	3.62x	6.39x	8.08x	10.91x	14.23x
FCF Conversion	0.97x	0.50x	0.08x	2.85x	0.80x	1.70x	1.51x	2.19x
Revenue Growth	-	-	2564.59%	91.21%	43.35%	32.93%	22.8%	21.51%

HRMY SEC Filings & Documents

Harmony Biosciences Holdings, Inc. (HRMY) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 14, 2026·SEC

Material company update

Apr 2, 2026·SEC

Material company update

Feb 24, 2026·SEC

10-K Annual Reports

FY 2026

Feb 24, 2026·SEC

FY 2025

Feb 25, 2025·SEC

FY 2024

Feb 22, 2024·SEC

10-Q Quarterly Reports

FY 2025

Nov 4, 2025·SEC

FY 2025

Aug 5, 2025·SEC

FY 2025

May 6, 2025·SEC

HRMY Frequently Asked Questions

Harmony Biosciences Holdings, Inc. (HRMY) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Harmony Biosciences Holdings, Inc. (HRMY) reported $868.5M in revenue for fiscal year 2025.

Harmony Biosciences Holdings, Inc. (HRMY) grew revenue by 21.5% over the past year. This is strong growth.

Yes, Harmony Biosciences Holdings, Inc. (HRMY) is profitable, generating $158.7M in net income for fiscal year 2025 (18.3% net margin).

Dividend & Returns

Harmony Biosciences Holdings, Inc. (HRMY) has a return on equity (ROE) of 20.8%. This is excellent, indicating efficient use of shareholder capital.

Harmony Biosciences Holdings, Inc. (HRMY) generated $347.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More HRMY

Harmony Biosciences Holdings, Inc. (HRMY) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Harmony Biosciences Holdings, Inc.(HRMY)Earnings, Financials & Key Ratios

HRMY Key Insights

✓Strengths

✗Weaknesses

HRMY Price & Volume

HRMY Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

HRMY Recent Earnings

HRMY Peer Comparison

Compare HRMY vs Peers

vs JAZZ

vs MCK

Compare Top 5

HRMY Income Statement

HRMY Balance Sheet

HRMY Cash Flow Statement

HRMY Key Ratios

HRMY SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

HRMY Frequently Asked Questions

Explore More HRMY

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation